Maintaining the trend we reported before, the Sixth Circuit has rejected the expert opinions offered by plaintiff in Simmons v. Novartis Pharmaceuticals Corp., No. 11-5053. The case is part of the multidistrict ligation (MDL) proceedings in relation to Zometa and Aredia, drugs used to treat bone problems in cancer patients and produced by Novartis. To make her case, the … Continue Reading
Adding to line of cases that started a year ago with Tamraz v. Lincoln Elec. Co., 620 F.3d 665 (6th Cir. 2010) (discussed here), the Sixth Circuit has again tightened the requirements for expert testimony under Rule 702 and Daubert in Thomas v. Novartis Pharmaceuticals Corp.pdf, Nos. 09-6147, 09-6272, 09-6274. As previously reported last September, a … Continue Reading
